

**Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3.**

Heremans, Yves; Van De Castele, Mark; In 't Veld, Pieter; Gradwohl, G.; Serup, Palle; Madsen, O.; Pipeleers, Daniel; Heimberg, Henry

*Published in:*  
J Cell Biology

*Publication date:*  
2002

*License:*  
Unspecified

*Document Version:*  
Final published version

[Link to publication](#)

*Citation for published version (APA):*  
Heremans, Y., Van De Castele, M., In 't Veld, P., Gradwohl, G., Serup, P., Madsen, O., Pipeleers, D., & Heimberg, H. (2002). Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3. *J Cell Biology*, 159, 303-312.

**Copyright**

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

**Take down policy**

If you believe that this document infringes your copyright or other rights, please contact [openaccess@vub.be](mailto:openaccess@vub.be), with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.

# Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3

Yves Heremans,<sup>1</sup> Mark Van De Casteele,<sup>1</sup> Peter in't Veld,<sup>1</sup> Gerard Gradwohl,<sup>2</sup> Palle Serup,<sup>3</sup> Ole Madsen,<sup>3</sup> Daniel Pipeleers,<sup>1</sup> and Harry Heimberg<sup>1</sup>

<sup>1</sup>Diabetes Research Center, Brussels Free University (VUB), B-1090 Brussels, Belgium

<sup>2</sup>Institut National de la Santé et de la Recherche Médicale, U381, Development and Pathology of the Digestive System, F-67200 Strasbourg, France

<sup>3</sup>Hagedorn Research Institute, DK-2820 Gentofte, Denmark

Regulatory proteins have been identified in embryonic development of the endocrine pancreas. It is unknown whether these factors can also play a role in the formation of pancreatic endocrine cells from postnatal nonendocrine cells. The present study demonstrates that adult human pancreatic duct cells can be converted into insulin-expressing cells after ectopic, adenovirus-mediated expression of the class B basic helix-loop-helix factor neurogenin 3 (*ngn3*), which is a critical factor in embryogenesis of the mouse endocrine pancreas. Infection with adenovirus *ngn3* (*Adngn3*) induced gene and/or protein expression of *NeuroD/β2*, *Pax4*, *Nkx2.2*, *Pax6*, and *Nkx6.1*,

all known to be essential for β-cell differentiation in mouse embryos. Expression of *ngn3* in adult human duct cells induced Notch ligands *Dll1* and *Dll4* and neuroendocrine- and β-cell-specific markers: it increased the percentage of synaptophysin- and insulin-positive cells 15-fold in *ngn3*-infected versus control cells. Infection with *NeuroD/β2* (a downstream target of *ngn3*) induced similar effects. These data indicate that the Delta-Notch pathway, which controls embryonic development of the mouse endocrine pancreas, can also operate in adult human duct cells driving them to a neuroendocrine phenotype with the formation of insulin-expressing cells.

## Introduction

Several studies have suggested that adult β-cells might originate from duct or duct-associated cells (Slack, 1995; Bouwens and Pipeleers, 1998; Edlund, 1999; Bonner-Weir et al., 2000). Evidence for this concept is largely indirect, and the underlying mechanisms are unknown. It is also conceivable that acinar cells can become a source of new β-cells in view of their plasticity, allowing them to transdifferentiate into hepatocytes (Shen et al., 2000) and into duct cells (Rooman et al., 2000). If postnatal acinar and/or duct cells could form new β-cells, they would become a particularly useful target

for therapies that aim β-cell replacement in diabetic patients (Keymeulen et al., 1998; Shapiro et al., 2000), since both cell types are abundantly available in the pancreas of these patients and in donor organs. To assess such potential, we examined whether expression of key embryonic transcription factors in adult human duct cells could induce their differentiation into insulin-expressing cells.


Experiments with transgenic mice have indicated key factors in the embryonic development of their endocrine pancreas. Analysis of null mutants for *Pdx1/Ipf1*, *ngn3*, *NeuroD/β2*, *Pax4*, *Nkx2.2*, *Nkx6.1*, or *Pax6* has identified a hierarchy of transcription factors that control embryonic formation of pancreatic islets (for review see Sander and German, 1997; Jensen et al., 2000a; Edlund, 2001). It is unknown whether these factors play a role in the postnatal growth of the pancreatic β-cell mass and whether they can be used to induce formation of human β-cells from postnatal nonendocrine cells. In this perspective, we examined the endocrinogenic potential of the class B basic helix-loop-helix (bHLH)\* transcription factor neurogenin 3 (*ngn3*), which seems to function

Address correspondence to Harry Heimberg, Diabetes Research Center, Brussels Free University (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium. Tel.: 32-2-477-4548. Fax: 32-2-477-4545.  
E-mail: hheimber@vub.vub.ac.be

\*Abbreviations used in this paper: Ad, adenovirus; bHLH, basic helix-loop-helix; CK, cytokeratin; CMV, cytomegalovirus; MOI, multiplicity of infection; *ngn3*, neurogenin 3.

Key words: neurogenin 3; islets of langerhans; transdifferentiation; insulin; diabetes mellitus

**Figure 1. Endogenous expression of key developmental transcription factors in adult human pancreatic duct cells.** (A) RT-PCR analysis of RNA extracted from adult human duct cells compared with adult human islet cells. (B) Nkx6.1 protein in adult human pancreas as determined by immunoblot of extracts from enriched duct or islet cells (MIN6 were control cells), and immunostaining on sections of human donor pancreas. Bars, 10  $\mu$ m.



as a major and timely switch in the rodent embryonic pancreas (Gradwohl et al., 2000). When expression of *ngn3* is directed ectopically into the embryonic epithelium, pancreas precursor cells develop prematurely and exclusively into glucagon-producing cells (Apelqvist et al., 1999; Schwitzgebel et al., 2000). Similarly, *ngn3* induced premature differentiation into glucagon- and somatostatin-producing cells when introduced into early chicken endoderm (Grapin-Botton et al., 2001). The failure to induce insulin-producing cells might indicate that these immature cells lack the competence to drive  $\beta$ -cell differentiation. The differentiating activity of *ngn3* is under control of Notch signaling. Indeed, null mutant mice for the Notch ligand *Dll1*, for an intracellular mediator of Notch signaling *RBP-Jk* (Apelqvist et al., 1999), or for a downstream bHLH repressor *HES1* (Jensen et al., 2000b), which possibly controls *ngn3* (Tanabe and Jessell, 1996), all show premature endocrine differentiation. Therefore, we ectopically expressed *ngn3* in adult duct cells to assess its role as a switch activating the expression of other developmental transcription factors and Delta-Notch proteins and consequently resulting in the appearance of endocrine differentiation markers, in particular insulin.

## Results


### Absence of regulators of embryonic endocrine differentiation in postnatal human pancreatic duct cells

Adult human  $\beta$ -cell preparations express a series of transcription factors that are crucial for embryonic development of mouse endocrine pancreas (Fig. 1 A). Transcripts encoding *Pdx1/Ipf1*, *NeuroD/β2*, *Pax4*, *Pax6*, *Nkx2.2*, and *Nkx6.1* were abundant in adult human islets. The expression of *Pax4* in human islets is at variance with its absence in postnatal mouse islets (Smith et al., 1999) or rat-purified  $\beta$ -cells (see Fig. 4 A). A parallel analysis of adult human duct cell transcripts shows the presence of relatively high levels *Pdx1/Ipf1* and *Nkx6.1* transcripts (Fig. 1 A). *Pdx1/Ipf1* is also expressed in adult human duct cells at the protein level (Heimberg et al., 2000), but this is not the case for *Nkx6.1* (Fig. 1 B), suggesting it is subject to posttranscriptional regulation. Sections of adult human pancreas with both  $\beta$ -cells and duct cells clearly indicated that *Nkx6.1*-positive nuclei


were associated with insulin-containing cells and not with cells that expressed the ductal cell marker CA19.9 (Bouwens and Pipeleers, 1998) (Fig. 1 B). *Ngn3* mRNA level was low in both islets and duct cells. Compared with islet cells, the duct cell levels of transcripts coding for Notch 1, 2, and 3 receptors were higher, those for Jagged 1 and 2 ligands were similar, and those for *Dll1* and *Dll4* ligands were much lower (see Fig. 3 C).

### *Ngn3* induces expression of regulators of embryonic endocrine differentiation in postnatal human pancreatic duct cells

We ectopically expressed *ngn3* and its downstream target *NeuroD/β2* in adult human duct cells. Common transfection methods were unsuccessful, but infection with recombi-



**Figure 2. Specificity and efficiency of adenovirus-mediated transgene expression.** Immunoblotted protein extracts (2  $\mu$ g total protein) (A) and immunostained monolayers (B) of noninfected and virally infected adult human pancreatic duct cells. Bars, 10  $\mu$ m.




**Figure 3. Effect of adenovirus-mediated ectopic expression of *ngn3* or NeuroD/β2 on key transcription factors and signal transduction proteins in adult duct cells.** (A) RT-PCR analysis of RNA encoding key developmental transcription factors from control and virus-infected duct cells and islets. Adngn3-expressed mouse *ngn3* and AdNeuroD/β2-expressed rat NeuroD/β2. (B) Analysis of the effects of *ngn3* (b, d, f, h, j, and l) compared with AdGFP-infected control cells (a, c, e, g, i, and k) at the cellular level by in situ hybridization of NeuroD/β2 (a and b) and Pax4 (c and d) mRNA and immunofluorescence for Nkx2.2 (e–h), *ngn3* (e and f), Nkx6.1 (i and j) and Pax6 (k and l). Sections for immunocytochemistry underwent short (1 h) fixation to preserve GFP fluorescence. Arrowheads in panel f point to cells expressing either Nkx2.2 or *ngn3* (intense red, respectively, green nuclear staining), and arrow points to a cell expressing Nkx2.2 and still containing GFP (weak green fluorescence in cytoplasm combined with weak red staining in the nucleus) without high level expression of *ngn3*. Panels g and h represent a combination of phase-contrast and fluorescence microscopy (Nkx2.2 immunostaining), emphasizing the massive effect of *ngn3*. Bars, 10 μm. (C) RT-PCR analysis of RNA encoding Notch, Jagged, and Delta isoforms from control and virus-infected duct cells and human islets.

nant adenoviruses (Ad) resulted in efficient expression of the transgenes that were under control of a cytomegalovirus (CMV) promoter (Fig. 2). Both Adngn3 and AdNeuroD/β2 coexpressed GFP as a reporter, and AdGFP served as control for nonspecific viral effects. A multiplicity of infection (MOI) of 50 gave a favorable balance between infection efficiency (30–40% GFP expression) (Fig. 2) and cell survival (>85% living cells).

1 d after *ngn3* infection, *Pax4* gene expression was activated (Fig. 3 A) together with *Dll1* and *Dll4*, the latter two to similar levels as in control islet preparations (Fig. 3 C). 2 d later, *NeuroD/β2* was induced, followed by *Nkx2.2* and *Pax6* (Fig. 3 A). The *Pdx1/Ip1f1* gene remained silent or constant in, respectively, monolayer or suspension cultures of Adngn3-infected duct cells (unpublished data). These effects were confirmed by in situ hybridization and immunocytochemistry. 10 d after infection, many cells expressed either

*Nkx2.2* or *ngn3* (Fig. 3 B, f, arrowheads) but rarely both. However, some *Nkx2.2*-expressing cells still contained GFP (Fig. 3 B, f, arrow). There was no significant increase in the level of *Nkx6.1*-encoding mRNA, but the protein appeared abundant (Fig. 3 B, j). Nuclear protein extracts from Adngn3-infected duct cells showed gel retardation of E box-1 and E box-3 sequences from the *NeuroD/β2* promoter (unpublished data). Compared with *ngn3*, NeuroD/β2-induced changes in gene expression were similar but appeared with a several days delay (unpublished data). The same recombinant Ad constructs were used to infect the clonal neuroendocrine cell line PC12 and the unrelated HeLa cell line. In PC12 cells, which endogenously express NeuroD/β2 and *Nkx2.2*, both *ngn3* and NeuroD/β2 induced *Pax4* but not *Nkx6.1* (Fig. 4 A). In HeLa cells, none of these endocrinogenic transcription factors were induced after infection with Adngn3 or AdNeuroD/β2.



**Figure 4. Effect of adenovirus-mediated expression of ngn3 or NeuroD/β2 in the neuroendocrine cell line PC12.** (A) RT-PCR analysis of RNA encoding Pax4 and insulin from control and virus-infected PC12 cells and purified rat β-cells. (B) Immunostaining of insulin in PC12 cells that were infected at low MOI with Adngn3. Arrow points to insulin-positive PC12 cell that still contains lots of active GFP; arrowheads point to PC12 cells that express insulin but contain no active GFP or ngn3 anymore. Bars, 10 μm.

### Ngn3 induces expression of neuroendocrine markers, in particular insulin, in postnatal human pancreatic duct cells

Control duct cell preparations were negative by RT-PCR analysis for the endocrine cell markers synaptophysin, chromogranin A, and prohormone convertases (PC1/3 and PC2), and for the islet cell markers insulin, somatostatin, glucagon, glucose transporter type II, and glucokinase. Transcripts encoding these proteins were clearly present in the human islet cell fraction (Fig. 5 A; not depicted). 10 d after infection with Adngn3 or AdNeuroD/β2, duct cell preparations exhibited a strong activation of synaptophysin, chromogranin A, and PC1/3 gene expression, and a weaker increase for the glucokinase and insulin genes (Fig. 5 A). No signals were detected for Glut2, somatostatin, or glucagon transcripts. These effects of ectopic ngn3 expression were also reflected at the protein level (Fig. 5 B). The fraction of cells that were immunopositive for insulin and synaptophysin increased from 1% in control preparations to, respectively, 13 and 22% 10 d after Adngn3 infection. The percentage of glucagon- or somatostatin-positive cells remained under 2% (unpublished data). However, although ectopic ngn3 did not affect the number of glucagon-containing cells, it increased the percentage of somatostatin-positive cells 3.5-fold ( $0.2 \pm 0.1\%$  versus  $0.7 \pm 0.1\%$ ,  $P < 0.05$ ;  $n = 4$ ). A similar effect was observed after infection with Ad-

**Table I. Effect of ngn3 or NeuroD/β2 on the fraction of granulated and synaptophysin- or insulin-positive cells**

	Granulation <sup>+</sup> <i>n</i> = 3	Synaptophysin <sup>+</sup> <i>n</i> = 3	Insulin <sup>+</sup> <i>n</i> = 3
	%	%	%
AdGFP	< 2	< 2	< 2
Adngn3	$10 \pm 2^a$	$22 \pm 4^a$	$13 \pm 3^a$
AdNeuroD/β2	$8 \pm 4^a$	$10 \pm 1^a$	$8 \pm 2^a$

Granulation was analyzed by EM and synaptophysin and insulin positivity by immunostaining. Results are the average  $\pm$  standard error of the mean of *n* independent duct cell preparations infected with AdGFP, Adngn3, or AdNeuroD/β2 expressed as a percentage of total cells.

<sup>a</sup> $P < 0.05$  versus AdGFP-infected duct cells as determined by the paired Student's *t* test.

NeuroD/β2. Interestingly, most cells that expressed these endocrine markers were negative for ngn3 (Fig. 5 B, b, c, and g, arrowheads point to single positive cells). At this time point, the percentage of ngn3-positive cells was markedly lower than at day 3. Furthermore, the rare ngn3-positive cells that coexpressed endocrine markers exhibited a much lower ngn3 fluorescence intensity than those that did not (Fig. 5 B, b and g, arrows).

10 d after Adngn3 infection, many but not all synaptophysin-positive cells expressed chromogranin A (Fig. 5 B, k and l). More than 90% of the synaptophysin-expressing cells were still positive for the duct cell marker cytokeratin (CK)19 (Fig. 5 B, i); however, this was the case for only part of the insulin- or somatostatin-positive cells (Fig. 5 B, h and j; not depicted). Electronmicrographs confirmed the presence of a large percentage of ngn3-infected cells with secretory granules (Table I) that were, however, smaller than the characteristic large granules of fully differentiated endocrine islet cells (Fig. 5 C).

Ectopic ngn3 or NeuroD/β2 expression in postnatal human pancreatic duct cells resulted in a threefold increase in the insulin content and insulin release of the preparations (Table II). In view of the 10-fold increase in the percentage of insulin-positive cells, these data suggest that the newly formed insulin-positive cells have a low insulin content.


In PC12 cells, ngn3 and NeuroD/β2 induced insulin expression, both at the transcript and protein level (Fig. 4) but failed to induce glucokinase, Glut2, somatostatin or glucagon. No ngn3-induced gene expression was seen in HeLa cells.

**Table II. Effect of ngn3 or NeuroD/β2 on the relative concentration of insulin in duct cells and duct cell culture medium**

	Insulin content <i>n</i> = 4	Insulin release <i>n</i> = 3
AdGFP	100	100
Adngn3	$250 \pm 60^a$	$340 \pm 20^a$
AdNeuroD/β2	$310 \pm 50^a$	$330 \pm 20^a$

Insulin release was measured as the amount of insulin that accumulated in the medium during 48 h. Results are the average  $\pm$  standard error of the mean of *n* independent duct cell preparations infected with AdGFP, Adngn3, or AdNeuroD/β2 expressed as percentage of AdGFP-infected control cells.

<sup>a</sup> $P < 0.05$  versus AdGFP-infected duct cells as determined by the paired Student's *t* test.



**Figure 5. Effect of adenovirus-mediated ectopic expression of *ngn3* or NeuroD/ $\beta$ 2 on markers of the differentiated endocrine phenotype in adult human duct cells.** (A) RT-PCR analysis of RNA encoding endocrine marker proteins in adult human duct cells and islet cells. (B) Immunostaining of control (AdGFP-) (a and f, inset) and Adngn3- (b and j) infected duct cells. Nuclei stained blue by DAPI (a, b, d, g, h, and j). All immunoreactions were labeled with a fluorescent secondary antibody except for panel f which was immunocytochemically stained (ABC peroxidase). Panel j represents a double labeling for CgA (FITC) and Syn (Cy3). Panels c and e represent a combination of phase-contrast and fluorescence microscopy. Noninfected and control-infected duct cells contained a low number of endocrine cells (<1% insulin positivity and <2% synaptophysin positivity). Endocrine marker proteins were chromogranin A (CgA), synaptophysin (Syn), prohormone convertase 1/3 (PC1/3), and insulin (Ins); duct cell marker was CK19. Noninfected and GFP control-infected duct cells contained none of the endocrine proteins under study as determined by costaining for the duct cell markers CK19 or CA19.9. Bars, 10  $\mu$ m. Sections for immunocytochemistry underwent overnight fixation which abolished GFP fluorescence. Arrowheads, single positive cells on panels b and c (either *ngn3* or CgA), g (insulin), and j (Syn); arrows, cells coexpressing CgA and *ngn3* (b), insulin and *ngn3* (g), or CgA and Syn (j). (C) Electron micrograph of control (a) and transdifferentiating (b) adult human pancreatic duct cells 10 d postinfection with AdGFP (a) or Adngn3 (b). Adngn3-infected cells display 180-nm secretory granules with a homogenous, electron dense matrix. Bars, 1  $\mu$ m.

## Discussion

The present study demonstrates that adenovirus-mediated delivery of *ngn3*, a key transcription factor for the generation of endocrine islet cells in mouse embryos, shifts adult human pancreatic duct cells into a neuroendocrine phenotype with expression of insulin in a significant fraction of transdifferentiated cells. It is unlikely that this effect requires the participation of Pdx1/Ipf1. This transcription factor is expressed in adult human pancreatic duct cell suspensions, be it at lower abundance and with a different phosphorylation status and DNA-binding activity compared with mature human islet cells (Heimberg et al., 2000); however, the *ngn3*-induced (neuro)endocrine differentiation was also achieved in duct cell monolayers, which are negative for Pdx1/Ipf1 (unpublished data). Of the known developmental transcription factors that operate downstream of Pdx1/Ipf1 to specifically control embryonic pancreas formation, *ngn3* comes first in sequence. *Ngn3* is a major regulator of lateral inhibition that controls endocrinogenesis in the embryonic

mouse pancreas (Apelqvist et al., 1999). It has been proposed as a marker for pancreatic islet progenitor cells during embryogenesis and in adult mice (Jensen et al., 2000a; Gu et al., 2002). The amplified signal for *ngn3* transcript in duct cells was similar to islets and suggests very low but specific expression in this cell fraction. Adenovirus-mediated overexpression of *ngn3* in adult human pancreatic duct cells was found to activate expression of neuroendocrine differentiation markers and of  $\beta$ -cell-specific genes *Pax4* and insulin. Despite their independence of Pdx1/Ipf1, the requirement for *ngn3* and the induction of *Pax4* and somatostatin expression suggest that the *ngn3*-transdifferentiated (neuro)endocrine cells resemble cells of the second rather than the first wave of pancreatic endocrinogenesis. The described effects are cell type restricted, since they were reproduced in the PC12 neuroendocrine cell line but not in HeLa cells.

It is unknown presently whether this forced transdifferentiation is restricted to a subpopulation of duct cells. A major proportion of *ngn3*-infected cells expressed the (neuro)en-

ocrine markers, but only a fraction was insulin positive. The sequential activation of a comprehensive set of (neuro)endocrine-specific genes rather than the existence of (sub)populations of cells expressing only few individual markers is characteristic for the induction of a coordinated differentiation program. Based on its rapid nature and independence of cell proliferation (unpublished data), this process likely represents immediate transdifferentiation of the duct cells without the need for an intermediate cellular state (Shen et al., 2000; Slack and Tosh, 2001). Transdifferentiated cells are characterized by coexpression of the duct cell marker CK19 and the neuroendocrine marker synaptophysin. Such double positive cells are virtually absent in noninfected duct cell preparations. The expression levels of both markers changed gradually and reciprocally with time after infection. Only little cytokeratin positivity was left in the cells that finally expressed insulin. A combination of the transient nature of the adenoviral expression system and the elimination of fluorescence by GFP after extended fixation allowed simple tracing of cell fate. A direct relation between the *ngn3*-infected duct cells and the cells that became positive for endocrine markers was observed. Rare cells coexpressed endocrine marker proteins and traces of *ngn3*, suggesting a causal relationship between expression of *ngn3* and the endocrine protein. Furthermore, several endocrine cells still contained the stable green fluorescent protein that remains present for days after its transcript, and consequently the mRNA encoding the less stable *ngn3* protein, have disappeared (Corish and Tyler-Smith, 1999).

The mechanism whereby *ngn3* induces duct cell differentiation into endocrine  $\beta$ -cells seems to involve activation of the *Pax4* and the *NeuroD*/ $\beta$ 2 promoter. *Ngn3* is known to activate *NeuroD*/ $\beta$ 2 expression in chicken embryos (Grapin-Botton et al., 2001), *Xenopus* embryos, and (neuro)endocrine cell lines (Huang et al., 2000). This is also the case in HeLa cells that had been transfected with E47, a class A bHLH heterodimerization partner of *ngn3* (Huang et al., 2000). Adult human duct cells contain high endogenous levels of E47 (unpublished data), allowing E-box binding of the ectopically expressed *ngn3* and activation of the *NeuroD*/ $\beta$ 2 promoter. The delayed induction of *NeuroD*/ $\beta$ 2 by *ngn3* suggests the existence of intermediate transcription factors. Moreover, the delay in *NeuroD*/ $\beta$ 2-induced *Pax4* activation compared with *ngn3* uncovers that both *Pax4* and *NeuroD*/ $\beta$ 2 are *ngn3* targets, instead of *Pax4* being downstream of *NeuroD*/ $\beta$ 2. The present study thus supplements the hierarchy model of transcription factors involved in the formation of embryonic  $\beta$ -cells (Schwitzgebel et al., 2000). It also demonstrates that the embryological program in mice can be recapitulated in postnatal human duct cells, leading to formation of insulin, and to a minor extent somatostatin-expressing cells. In experimental terms, adult duct cells infected with adenoviruses expressing recombinant transcription factors are a simple *in vitro* model for studying the molecular biology of endocrine transdifferentiation.

Ectopic expression of *ngn3* or *NeuroD*/ $\beta$ 2 in isolated adult duct cells activates several (neuro)endocrine-specific genes, such as insulin and somatostatin, but not glucagon. In mouse or chicken embryonic endoderm cells *in vivo*, ectopic *ngn3* induces glucagon but not insulin (Grapin-Bot-

ton et al., 2001). Activation of  $\beta$ -cell-specific *Pax4* in duct cells might be responsible for the absence of glucagon expression (Smith et al., 1999; Petersen et al., 2000). The role of *Nkx2.2* and *Nkx6.1* in this transdifferentiation process is unclear: *Nkx2.2* was stimulated by *ngn3* at the transcriptional level, and *Nkx6.1* was stimulated at the posttranscriptional level. Both transcription factors appear essential during embryonic development of  $\beta$ -cells, with *Nkx2.2* acting upstream of *Nkx6.1* (Sander et al., 2000). *Adngn3*-infected duct cells failed to generate glucose-induced insulin release within the limits of the present study, i.e., 10 d after infection (unpublished data). Our study can thus not be taken as evidence for the ability to produce functionally mature  $\beta$ -cells from pancreatic duct cells. Nevertheless, the data are indicative for a selective ability of adult duct cells to differentiate toward (neuro)endocrine and islet cells. *Ngn3* induced moderate to high expression of synaptophysin, chromogranin A, *PC1/3*, and glucokinase, but the degree of insulin gene activation is low and so is the cellular insulin content. Transdifferentiated pancreatic duct cells exhibit the ultrastructural characteristics of immature endocrine cells, which is consistent with the absence of a glucose-regulated secretory activity. The absence of *Glut2* induction is compatible with the earlier report that *Glut2* is poorly expressed in human  $\beta$ -cells compared with human liver cells or rodent  $\beta$ -cells (De Vos et al., 1995).

The incomplete differentiation of this particular phenotype might be caused by, or related to, a variety of factors. (a) Although *Pax4* is subject to autoregulation in mouse islet cell lines (Smith et al., 2000), *ngn3*-induced activation of *Pax4* in human duct cells was not. This allows the relatively high levels of *Pax4* to exert their inhibitory action on insulin gene expression (Qiu et al., 1998; Smith et al., 1999). Low levels of *Pax4* also occurred in normal adult human islet cells in contrast to its restriction to the embryonic mouse pancreas (Sosa-Pineda et al., 1997; Smith et al., 1999, 2000). It is likely that in mature islet  $\beta$ -cells a yet unknown factor overrules the *Pax4* repressor activity. Given the transient presence of *ngn3* and *Pax4* in the embryonic mouse pancreas, it needs to be investigated whether a closer simulation of the embryonic situation by conditional expression of *ngn3* in adult human duct cells would augment the insulin levels. (b) The state of the Delta-Notch pathway probably also has its influence on the degree of (neuro)endocrinogenesis. In uninfected duct cells, high levels of *Notch1*, 2, and 3 but not of *Dll1*, 3, and 4 were found. *Ngn3* infection activated transcription of *Dll1* and *Dll4* and thus increased Notch signaling in neighboring pairs, which is expected to limit overall endocrine differentiation. It may thus be useful to add antimorphic forms of Delta that antagonize Notch signaling (Jen et al., 1997) or to introduce *ngn3* targets that bypass stimulation of Delta genes in order to specifically drive the formation of endocrine cells. (c) The transdifferentiated cells likely are dependent on extracellular factors to promote their maturation. (d) Finally, repression of specific proneural regulators induced by *ngn3* may be necessary to allow full endocrine differentiation. Although the transdifferentiated duct cells did not express genes that label differentiated neuronal cells (N-Cam, neurofilament, peripherin, and class III  $\beta$ -tubulin [unpublished data]), major overlaps exist between the

expression profile of endocrine pancreas and neurons (Atouf et al., 1997; unpublished data). These similarities were key to design conditions that drive embryonic stem cells to insulin production (Lumelsky et al., 2001). Moreover, insulin-producing cells are present in primary cell cultures from mammalian fetal brain (Clarke et al., 1986), and insulin-producing neurons in *Drosophila* brain show remarkable similarities with  $\beta$ -cells in mammalian islets of Langerhans (Rulifson et al., 2002). All these data are highly suggestive for a common ancestral insulin-producing cell of neural origin, which complicates the identification of specific proneural factors that are nonessential for islet cell differentiation.

In more general terms, the present findings extend the role of lateral inhibition in cell differentiation from embryonic, poorly differentiated tissues (Artavanis-Tsakonas et al., 1999) to postnatal differentiated cell populations. Adult human duct cells were shown to transdifferentiate into neuroendocrine and into insulin-producing cells after ectopic expression of *ngn3*. Pancreatic duct and islet cells have a common embryonic progenitor, but according to a recent lineage tracing study *ngn3* is never expressed in duct cells or their progenitors (Gu et al., 2002). However, our current study shows that *ngn3* might serve as a master switch that drives transdifferentiation to a (neuro)endocrine phenotype when misexpressed in adult duct cells. It is still unknown whether *ngn3* can be activated by environmental factors in normal duct cells of regenerating postnatal pancreas and thus result in the formation of new  $\beta$ -cells. Current efforts focus on finding ways to differentiate embryonic stem cells into insulin-producing cells with the purpose of producing sufficient cells for transplantation in diabetes (Assady et al., 2001; Lumelsky et al., 2001). Our observations have indicated mechanisms through which adult duct cells could be forced to differentiate into insulin-producing cells. The abundance of duct cells and the ease of their *in vitro* manipulation support further attempts to explore their potential as a source for new  $\beta$ -cells.

## Materials and methods

### Production of recombinant adenoviruses

Adenoviral plasmid pAdEasy-1 and shuttle vector pAdTrack-CMV were made available by T.-C. He and B. Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD). Coding sequences of hemagglutinin-tagged mouse *ngn3* or rat *NeuroD/β2* were subcloned in the shuttle vector and constitutively expressed under control of the CMV promoter. pAdTrack-CMV contained the eGFP cDNA downstream of a separate CMV promoter. Recombinant, replication-deficient adenoviruses expressing GFP (AdGFP), *ngn3* in combination with GFP (Ad*ngn3*), or *NeuroD/β2* in combination with GFP (Ad*NeuroD/β2*) were generated following the standard protocol as described by He et al. (1998).

### Cell isolation and cell culture

The duct cells in this study were obtained from heart-beating cadaveric nondiabetic donors as the discarded fraction of an islet cell isolation to prepare grafts for transplantation in type I diabetes patients. Human donor pancreases were procured at European hospitals and made available to the  $\beta$ -Cell Bank in Brussels through the intermediate of Eurotransplant Foundation (Leiden, The Netherlands). The endocrine preparations contained >60% hormone-positive cells (Keymeulen et al., 1998). In the nonendocrine fraction, <2% expressed islet cell markers and >90% expressed the duct cell-specific phenotypic markers cytokeratin 19 and carbohydrate antigen 19.9 when cultured for at least 4 d (Bouwens et al., 1994). The nonendocrine cell preparation was cultured in suspension in Ham's F10 (Bio-Whittaker), 0.5% BSA (Boehringer Mannheim), 7.5 mM glucose, 100

U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 1 mM L-glutamine at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. 24 h after isolation, the cells were washed, and the medium was renewed. On day 4 of culture, cells were counted and were infected and further cultured in suspension. Alternatively, day 4 cells were plated to form monolayers in the presence of 5% FBS (Life Technologies) and infected 6 d later. Under all conditions, cell culture medium was renewed every other day.

PC12 cells were cultured in suspension in RPMI 1640 with Glutamax (Life Technologies), 10% FBS, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. Rat  $\beta$ -cells were prepared as described before (Heimberg et al., 1996).

### Viral infection of isolated exocrine cells and PC12 cells

Cells were either infected with control virus (AdGFP) or with Ad*ngn3* or Ad*NeuroD/β2* as described previously (Heimberg et al., 2001). Adult human duct cells were infected at an MOI of 50 for 4 h at 37°C. PC12 cells were infected at an MOI 20 for 4 h at 37°C.

### Protein analysis

Immunohistochemical analysis was performed on 4- $\mu$ m-thick paraffin sections by indirect immunofluorescence as described (Heimberg et al., 2000). Similar methods were applied to cells from suspension cultures after fixation for 1 h in 4% paraformaldehyde and pelleting in 2% agarose before paraffin embedding. Before incubation with the first antibody, sections for CK19 staining were trypsin treated. Rabbit polyclonal PC1/3 antiserum was from I. Lindberg (Louisiana State University Health Sciences Center, New Orleans, LA) (Vindrola and Lindberg, 1992), rabbit polyclonal anti-*ngn3* was from M. German (University of California San Francisco, San Francisco, CA), rabbit polyclonal Pax6 was from S. Saule (Institut Curie, Paris, France), and guinea pig polyclonal insulin was from C. Van Schravendijck (Brussels Free University). The mouse monoclonal anti-Nkx2.2 was developed by T. Jessell (Columbia University, New York, NY) and obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). Rabbit polyclonal anti-Nkx6.1 has been described before (Oster et al., 1998). Rabbit polyclonal antisomatostatin was from J. DeMey (Brussels Free University), mouse monoclonal anti-chromogranin A was from Biogenex, rabbit polyclonal antisynaptophysin was from Novocastra, mouse monoclonal anti-cytokeratin 19 was from Dako, mouse monoclonal anti-CA19-9 from Biomed, and mouse monoclonal anti-HA was from Boehringer. Secondary antibodies were Cy3- or FITC-labeled anti-rabbit, anti-mouse, and anti-guinea pig (Jackson ImmunoResearch Laboratories). Immunoblot analysis was done as described before (Heimberg et al., 2000).

### mRNA analysis

Total RNA was isolated using RNEasy columns (QIAGEN) and reverse transcription followed by PCR were performed and analyzed as described (Heimberg et al., 1996). Primers specifically amplified human *Pdx1/Ipf1* (277 bp), 5'-CTGCCTTTCCCATGGATGAA-3' (forward) and 5'-CGCTTCTGTCTCCTCCTT-3' (reverse), human *ngn3* (286 bp), 5'-AGACGACGGC-GAAGCTCACC-3' (forward) and 5'-AAGCCAGACTGCCTGGGCT-3' (reverse), human *NeuroD/β2* (439 bp), 5'-ATCCCAACCCACCAACC-3' (forward) and 5'-CAGCGGTGCTGAGAAAGATT-3' (reverse), human Pax4 (496 bp), 5'-AGGAGGACCAGGGACTACCGT-3' (forward) and 5'-TTT-AGGTGGGGTCTACTCAG-3' (reverse), human Pax6 (301 bp), 5'-CAAAAGTCCAAGTGCTGGACAA-3' (forward) and 5'-CCCATCTGTGCTTTTCGCT-3' (reverse), human *Nkx2.2* (329 bp), 5'-TGCAGCACAT-GCAGTACAACG-3' (forward) and 5'-TCCAAGTTCAGAAGGAGAGG-3' (reverse), human *Nkx6.1* (284 bp), 5'-TCTTCTGGCCCGGGGTGATG-3' (forward) and 5'-AGCCCGCTGCTTCTTCTCC-3' (reverse), human *Notch1* (160 bp), 5'-GAATCCAACCCCTTGTGTAAC-3' (forward) and 5'-GCAACGTCGTAATACACGTG-3' (reverse), human *Notch2* (231 bp), 5'-CGCTGATTGACCTGGTCAAT-3' (forward) and 5'-TACATGTTGCAC-CCTTGCGA-3' (reverse), mouse *Notch3* (240 bp), 5'-GGCATTGCTAGCT-TCTCGTGT-3' (forward) and 5'-CATAACGGTTGATGCCATCAC-3' (reverse), human *Jagged1* (417 bp), 5'-ATCTGTCCACCTGGCTATGCAG-3' (forward) and 5'-ATTTGCTCCCGACTGACTCTT-3' (reverse), human *Jagged2* (338 bp), 5'-GGAAGCCATGCCTTAACGCTT-3' (forward) and 5'-GCTCAAAGGTCGACATCCA-3' (reverse), human *Delta1* (309 bp), 5'-CCTGATGACCTCGCAACAGAA-3' (forward) and 5'-CATGCTGCTCAT-CACATCCAG-3' (reverse), human *Delta4* (273 bp), 5'-ACCACCTCGG-CACTATGTGT-3' (forward) and 5'-TCTTGGTCACAAAACGGCT-3' (reverse), human synaptophysin (214 bp), 5'-GCCACATGCGGCAGCTA-CAG-3' (forward) and 5'-ACACGGCCACGGTGACAAAG-3' (reverse), human chromogranin A (286 bp), 5'-CCGCTGTCTGGCTCTTCT-3' (forward) and 5'-CCGCTGTGTTTCTTCTGCTG-3' (reverse), human/rat insulin



(438 bp), 5'-GCAGCCTTTGTGAACCAACA-3' (forward) and 5'-TCTGCG-GTCATCAAAATGAGG-3' (reverse), human glucagon (221 bp), 5'-CCCAA-GATTTTGTGCAGTGGTT-3' (forward) and 5'-GCGGCCAAGTCTTCAA-CAAT-3' (reverse), human glucokinase (607 bp), 5'-CTGGACGACA-GAGCCAGGAT-3' (forward) and 5'-TCACCATTGCCACCACATCCAT-3' (reverse), human PC1/3 (355 bp), 5'-CAAGATACCAGGATGACGGCA-3' (forward) and 5'-GCCCTAATAGCATCCGTCACA-3' (reverse), mouse ngn3 (288 bp), 5'-CCGGATGACGCCAAACTTACA-3' (forward) and 5'-ACAC-CAGTGCTCCCGGGAG-3' (reverse), rat NeuroD/Beta2 (300 bp), 5'-GGACTTTCTTGCTGAGCAGA-3' (forward) and 5'-AACTCGGTGGATG-TTTCGTGT-3' (reverse), rat Pax4 (224 bp), 5'-ATGCGACCTGTGA-CATCTCA-3' (forward) and 5'-AAGCCCTTCAGCACAAAGCTG-3' (reverse), rat Nkx2.2 (209 bp), 5'-CATGTCGCTGACCAACACAAAG-3' (forward) and 5'-TCGCTGCTGCTAGAAAGGA-3' (reverse), and rat/human  $\beta$ -actin (361 bp), 5'-AGAGCTATGAGCTGCCTGAC-3' (forward) and 5'-CTGATCCACATCTGCTGGA-3' (reverse). For in situ hybridization, human-specific NeuroD/B2, Pax4, and ngn3 PCR products were subcloned into the pGEM-T Easy vector (Promega) and SalI linearized (Life Technologies). Digoxigenin-labeled transcripts were produced according to manufacturer's instructions (MAXI Script; Ambion). RNA in situ hybridization was performed as described (Gradwohl et al., 2000; Petersen et al., 2000). Detection of hybridized probes made use of an alkaline phosphatase-labeled antidigoxigenin antibody (Boehringer) and the substrate BM-Purple (Boehringer).

### Electron microscopy

Cell preparations were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), postfixed in 1% osmium tetroxide, stained with 2% uranyl acetate, embedded in Spurr's resin, and ultra thin plastic sections were examined with a ZEISS EM 9S2 electron microscope.

### Data analysis

Results obtained from infected cells were compared with uninfected and/or control virus-infected cells and statistically analyzed using the paired Student's *t* test.

Bert Vogelstein, Mike German, Simon Saule, Iris Lindberg, and Chris Van Schravendijck are acknowledged for viral vectors and antisera. We are grateful to Steven De Vos, Jan De Jonge, Karen Sterck, Veerle Lauryens, Mette Jorgensen, Marjorie Jenny, Luc Bouwens, and Jorge Ferrer for technical help, discussions, and critical advice.

The authors are members of the Juvenile Diabetes Research Foundation Center for  $\beta$ -Cell Therapy in Europe. Harry Heimberg is recipient of a Career Development Award from the Juvenile Diabetes Research Foundation and a Post-Doctoral Research Fellowship from the Fund for Scientific Research (Flanders, Belgium).

Submitted: 15 March 2002

Revised: 28 August 2002

Accepted: 28 August 2002

## References

- Apelqvist, A., H. Li, L. Sommer, P. Beatus, D.J. Anderson, T. Honjo, M. Hrabe de Angelis, U. Lendahl, and H. Edlund. 1999. Notch signalling controls pancreatic cell differentiation. *Nature*. 400:877–881.
- Artavanis-Tsakonas, S., M.D. Rand, and R.J. Lake. 1999. Notch signaling: cell fate control and signal integration in development. *Science*. 284:770–776.
- Assady, S., G. Maor, M. Amit, J. Itskovitz-Eldor, K.L. Skorecki, and M. Tzukerman. 2001. Insulin production by human embryonic stem cells. *Diabetes*. 50:1691–1697.
- Atouf, F., P. Czernichow, and R. Scharfmann. 1997. Expression of neuronal traits in pancreatic beta cells. Implication of neuron-restrictive silencing factor/repressor element silencing transcription factor, a neuron-restrictive silencer. *J. Biol. Chem.* 272:1929–1934.
- Bonner-Weir, S., M. Taneja, G.C. Weir, K. Tatarkiewicz, K.H. Song, A. Sharma, and J.J. O'Neil. 2000. In vitro cultivation of human islets from expanded ductal tissue. *Proc. Natl. Acad. Sci. USA*. 97:7999–8004.
- Bouwens, L., and D.G. Pipeleers. 1998. Extra-insular beta cells associated with ductules are frequent in adult human pancreas. *Diabetologia*. 41:629–633.
- Bouwens, L., R.N. Wang, E. De Blay, D.G. Pipeleers, and G. Kloppel. 1994. Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. *Diabetes*. 43:1279–1283.
- Clarke, D.W., L. Mudd, F.T. Boyd, Jr., M. Fields, and M.K. Raizada. 1986. Insulin is released from rat brain neuronal cells in culture. *J. Neurochem.* 47:831–836.
- Corish, P., and C. Tyler-Smith. 1999. Attenuation of green fluorescent protein half-life in mammalian cells. *Protein Eng.* 12:1035–1040.
- De Vos, A., H. Heimberg, E. Quartier, P. Huypens, L. Bouwens, D. Pipeleers, and F. Schuit. 1995. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. *J. Clin. Invest.* 96:2489–2495.
- Edlund, H. 1999. Pancreas: how to get there from the gut? *Curr. Opin. Cell Biol.* 11:663–668.
- Edlund, H. 2001. Factors controlling pancreatic cell differentiation and function. *Diabetologia*. 44:1071–1079.
- Gradwohl, G., A. Dierich, M. LeMeur, and F. Guillemot. 2000. Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci. USA*. 97:1607–1611.
- Grapin-Botton, A., A.R. Majithia, and D.A. Melton. 2001. Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. *Genes Dev.* 15:444–454.
- Gu, G., J. Dubauskaite, and D.A. Melton. 2002. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development*. 129:2447–2457.
- He, T.C., S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA*. 95:2509–2514.
- Heimberg, H., A. De Vos, K. Moens, E. Quartier, L. Bouwens, D. Pipeleers, E. Van Schaffingen, O. Madsen, and F. Schuit. 1996. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. *Proc. Natl. Acad. Sci. USA*. 93:7036–7041.
- Heimberg, H., L. Bouwens, Y. Heremans, M. Van De Casteele, V. Lefebvre, and D. Pipeleers. 2000. Adult human pancreatic duct and islet cells exhibit similarities in expression and differences in phosphorylation and complex formation of the homeodomain protein Ip-1. *Diabetes*. 49:571–579.
- Heimberg, H., Y. Heremans, C. Jobin, R. Leemans, A.K. Cardozo, M. Darville, and D.L. Eizirik. 2001. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. *Diabetes*. 50:2219–2224.
- Huang, H.P., M. Liu, H.M. El-Hodiri, K. Chu, M. Jamrich, and M.J. Tsai. 2000. Regulation of the pancreatic islet-specific gene BETA2 (neuroD) by neurogenin 3. *Mol. Cell. Biol.* 20:3292–3307.
- Jen, W.C., D. Wettstein, D. Turner, A. Chitnis, and C. Kintner. 1997. The Notch ligand, X-Delta-2, mediates segmentation of the paraxial mesoderm in *Xenopus* embryos. *Development*. 124:1169–1178.
- Jensen, J., R.S. Heller, T. Funder-Nielsen, E.E. Pedersen, C. Lindsell, G. Weinmaster, O.D. Madsen, and P. Serup. 2000a. Independent development of pancreatic alpha- and beta-cells from neurogenin3-expressing precursors: a role for the notch pathway in repression of premature differentiation. *Diabetes*. 49:163–176.
- Jensen, J., E.E. Pedersen, P. Galante, J. Hald, R.S. Heller, M. Ishibashi, R. Kageyama, F. Guillemot, P. Serup, and O.D. Madsen. 2000b. Control of endodermal endocrine development by Hes-1. *Nat. Genet.* 24:36–44.
- Keymeulen, B., Z. Ling, F.K. Gorus, G. Delvaux, L. Bouwens, A. Gruppig, C. Hendrickx, M. Pipeleers-Marichal, C. Van Schravendijck, K. Salmela, and D.G. Pipeleers. 1998. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. *Diabetologia*. 41:452–459.
- Lumelsky, N., O. Blondel, P. Laeng, I. Velasco, R. Ravin, and R. McKay. 2001. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. *Science*. 292:1389–1394.
- Oster, A., J. Jensen, H. Edlund, and L.I. Larsson. 1998. Homeobox gene product Nkx 6.1 immunoreactivity in nuclei of endocrine cells of rat and mouse stomach. *J. Histochem. Cytochem.* 46:717–721.
- Petersen, H.V., M.C. Jorgensen, F.G. Andersen, J. Jensen, T.F. Nielsen, R. Jorgensen, O.D. Madsen, and P. Serup. 2000. Pax4 represses pancreatic glucagon gene expression. *Mol. Cell. Biol. Res. Commun.* 3:249–254.
- Qiu, C., M.B. De Young, A. Finn, and D.A. Dichek. 1998. Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and alpha(v)-integrins. *Hum. Gene Ther.* 9:507–520.
- Rooman, I., Y. Heremans, H. Heimberg, and L. Bouwens. 2000. Modulation of rat pancreatic acinoductal transdifferentiation and expression of PDX-1 in vitro. *Diabetologia*. 43:907–914.
- Rulifson, E.J., S.K. Kim, and R. Nusse. 2002. Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. *Science*. 296:1118–1120.
- Sander, M., and M.S. German. 1997. The beta cell transcription factors and devel-

- opment of the pancreas. *J. Mol. Med.* 75:327–340.
- Sander, M., L. Sussel, J. Connors, D. Scheel, J. Kalamaras, F. Dela Cruz, V. Schwitzgebel, A. Hayes-Jordan, and M. German. 2000. Homeobox gene *Nkx6.1* lies downstream of *Nkx2.2* in the major pathway of beta-cell formation in the pancreas. *Development.* 127:5533–5540.
- Schwitzgebel, V.M., D.W. Scheel, J.R. Connors, J. Kalamaras, J.E. Lee, D.J. Anderson, L. Sussel, J.D. Johnson, and M.S. German. 2000. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. *Development.* 127:3533–3542.
- Shapiro, A.M., J.R. Lakey, E.A. Ryan, G.S. Korbutt, E. Toth, G.L. Warnock, N.M. Kneteman, and R.V. Rajotte. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N. Engl. J. Med.* 343:230–238.
- Shen, C.N., J.M. Slack, and D. Tosh. 2000. Molecular basis of transdifferentiation of pancreas to liver. *Nat. Cell Biol.* 2:879–887.
- Slack, J.M. 1995. Developmental biology of the pancreas. *Development.* 121:1569–1580.
- Slack, J.M., and D. Tosh. 2001. Transdifferentiation and metaplasia—switching cell types. *Curr. Opin. Genet. Dev.* 11:581–586.
- Smith, S.B., H.C. Ee, J.R. Connors, and M.S. German. 1999. Paired-homeodomain transcription factor *PAX4* acts as a transcriptional repressor in early pancreatic development. *Mol. Cell. Biol.* 19:8272–8280.
- Smith, S.B., H. Watada, D.W. Scheel, C. Mrejen, and M.S. German. 2000. Autoregulation and maturity onset diabetes of the young transcription factors control the human *PAX4* promoter. *J. Biol. Chem.* 275:36910–36919.
- Sosa-Pineda, B., K. Chowdhury, M. Torres, G. Oliver, and P. Gruss. 1997. The *Pax4* gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature.* 386:399–402.
- Tanabe, Y., and T.M. Jessell. 1996. Diversity and pattern in the developing spinal cord. *Science.* 274:1115–1123.
- Vindrola, O., and I. Lindberg. 1992. Biosynthesis of the prohormone convertase mPC1 in ArT-20 cells. *Mol. Endocrinol.* 6:1088–1094.